Morgan Stanley Alkermes Plc. Call Options Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALKS
# of Institutions
393Shares Held
176MCall Options Held
558KPut Options Held
427K-
Black Rock Inc. New York, NY29.1MShares$917 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.5MShares$583 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10MShares$316 Million0.03% of portfolio
-
State Street Corp Boston, MA8.21MShares$259 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.41MShares$202 Million1.86% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $5.18B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...